Heart failure in patients with chronic kidney disease: A systematic integrative review

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Segall, Liviu ^a   Nistor, Ionut ^a   Covic, Adrian ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANEMIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DATA BASE; DIALYSIS; END STAGE RENAL DISEASE; EVIDENCE BASED PRACTICE; HEART FAILURE; HUMAN; HYPERVOLEMIA; INFORMATION RETRIEVAL; MEDICAL RECORD; QUANTITATIVE STUDY; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION; GLOMERULUS FILTRATION RATE; MORTALITY; PATHOLOGY; RISK FACTOR;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84901771190     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/937398     Document Type: Review

References (203)

1. U.S. Renal Data System (USRDS), Chronic kidney disease in the adult NHANES population. USRDS Annual Report Data 2009. http://www.usrds.org/2009/pdf/ V1-01-09.PDF
2. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. The American Journal of Kidney Diseases 1998 32 5, supplement 3 S112 S119 2-s2.0-0031733696 (Pubitemid 28527268)
3. Johnson D. W., Craven A., Isbel N. M., Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodialysis International 2007 11 1 1 14 2-s2.0-33846390391 10.1111/j.1542-4758.2007.00146.x (Pubitemid 46128673)
4. Bagshaw S. M., Cruz D. N., Aspromonte N., Daliento L., Ronco F., Sheinfeld G., Anker S. D., Anand I., Bellomo R., Berl T., Bobek I., Davenport A., Haapio M., Hillege H., House A., Katz N., Maisel A., Mankad S., McCullough P., Mebazaa A., Palazzuoli A., Ponikowski P., Shaw A., Soni S., Vescovo G., Zamperetti N., Zanco P., Ronco C., Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation 2010 25 5 1406 1416 2-s2.0-77951678489 10.1093/ndt/gfq066
5. Kottgen A., Russell S. D., Loehr L. R., Crainiceanu C. M., Rosamond W. D., Chang P. P., Chambless L. E., Coresh J., Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. Journal of the American Society of Nephrology 2007 18 4 1307 1315 2-s2.0-34047208743 10.1681/ASN.2006101159 (Pubitemid 46536917)
6. Soucie J. M., McClellan W. M., Early death in dialysis patients: risk factors and impact on incidence and mortality rates. Journal of the American Society of Nephrology 1996 7 10 2169 2175 (Pubitemid 27468246)
7. Harnett J. D., Foley R. N., Kent G. M., Barre P. E., Murray D., Parfrey P. S., Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney International 1995 47 3 884 890 2-s2.0-0028953102
8. Wang A. Y., Wang M., Lam C. W., Chan I. H., Lui S., Sanderson J. E., Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clinical Journal of the American Society of Nephrology 2011 6 4 805 812 2-s2.0-79955563490 10.2215/CJN.07130810
9. Trespalacios F. C., Taylor A. J., Agodoa L. Y., Bakris G. L., Abbott K. C., Heart failure as a cause for hospitalization in chronic dialysis patients. The American Journal of Kidney Diseases 2003 41 6 1267 1277 2-s2.0-0038100397 10.1016/S0272-6386(03)00359-7 (Pubitemid 36637983)
10. Foley R. N., Parfrey P. S., Harnett J. D., Kent G. M., Martin C. J., Murray D. C., Barre P. E., Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International 1995 47 1 186 192 2-s2.0-0028939185
11. Glassock R. J., Pecoits-Filho R., Barberato S. H., Left ventricular mass in chronic kidney disease and ESRD. Clinical Journal of the American Society of Nephrology 2009 4 1 S79 S91 2-s2.0-73849100028 10.2215/CJN.04860709
12. Herzog C. A., Asinger R. W., Berger A. K., Charytan D. M., Díez J., Hart R. G., Eckardt K., Kasiske B. L., McCullough P. A., Passman R. S., Deloach S. S., Pun P. H., Ritz E., Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney International 2011 80 6 572 586 2-s2.0-80052296951 10.1038/ki.2011.223
13. Cerasola G., Nardi E., Palermo A., Mulè G., Cottone S., Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. Journal of Nephrology 2011 24 1 1 10 2-s2.0-78651097847 10.5301/JN.2010.2030
14. Zoccali C., Benedetto F. A., Tripepi G., Mallamaci F., Cardiac consequences of hypertension in hemodialysis patients. Seminars in Dialysis 2004 17 4 299 303 2-s2.0-4243184788 10.1111/j.0894-0959.2004.17331.x (Pubitemid 39107654)
15. López B., González A., Hermida N., Laviades C., Díez J., Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International 2008 74 111 S19 S23 2-s2.0-57049166438 10.1038/ki.2008.512
16. Amann K., Breitbach M., Ritz E., Mall G., Myocyte/capillary mismatch in the heart of uremic patients. Journal of the American Society of Nephrology 1998 9 6 1018 1022 2-s2.0-0031748239
17. Ritz E., Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney International 2009 75 8 771 773 2-s2.0-63849328147 10.1038/ki.2009.35
18. Gross M., Ritz E., Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Seminars in Dialysis 2008 21 4 308 318 2-s2.0-48049101411 10.1111/j.1525-139X.2008.00454.x
19. Ritz E., Wanner C., The challenge of sudden death in dialysis patients. Clinical Journal of the American Society of Nephrology 2008 3 3 920 929 2-s2.0-44649181666 10.2215/CJN.04571007
20. Middleton R. J., Parfrey P. S., Foley R. N., Left ventricular hypertrophy in the renal patient. Journal of the American Society of Nephrology 2001 12 5 1079 1084 2-s2.0-0035028688 (Pubitemid 32378350)
21. Nardi E., Palermo A., Mulè G., Cusimano P., Cottone S., Cerasola G., Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. Journal of Hypertension 2009 27 3 633 641 2-s2.0-67649540424 10.1097/HJH.0b013e3283220ecd
22. Marchais S. J., Metivier F., Guerin A. P., London G. M., Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrology Dialysis Transplantation 1999 14 9 2178 2183 2-s2.0-0032780460 10.1093/ndt/14.9.2178 (Pubitemid 29403408)
23. Strózecki P., Adamowicz A., Nartowicz E., Odrowz-Sypniewska G., Włodarczyk Z., Manitius J., Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Renal Failure 2001 23 1 115 126 2-s2.0-0035092519 10.1081/JDI-100001291 (Pubitemid 32207300)
24. Chue C. D., Edwards N. C., Moody W. E., Steeds R. P., Townend J. N., Ferro C. J., Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012 98 3 219 224 2-s2.0-84555187981 10.1136/heartjnl-2011-300570
25. Galetta F., Cupisti A., Franzoni F., Femia F. R., Rossi M., Barsotti G., Santoro G., Left ventricular function and calcium phosphate plasma levels in uraemic patients. Journal of Internal Medicine 2005 258 4 378 384 2-s2.0-25444459121 10.1111/j.1365-2796.2005.01544.x (Pubitemid 41368689)
26. Raizada V., Hillerson D., Amaram J. S., Skipper B., Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. Journal of Investigative Medicine 2012 60 5 785 791
27. Steigerwalt S., Zafar A., Mesiha N., Gardin J., Provenzano R., Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. The American Journal of Nephrology 2007 27 2 159 163 2-s2.0-34247164635 10.1159/000100106 (Pubitemid 46588181)
28. Grassi G., Seravalle G., Ghiadoni L., Tripepi G., Bruno R. M., Mancia G., Zoccali C., Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2011 6 11 2620 2627 2-s2.0-80655126755 10.2215/CJN.06970711
29. National Institute of Clinical Excellence Chronic Heart Failure (NICE), National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care 2003 London, UK Royal College of Physicians. http://guidance. nice.org.uk/CG5
30. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J. J. V., Ponikowski P., Poole-Wilson P. A., Strömberg A., van Veldhuisen D. J., Atar D., Hoes A. W., Keren A., Mebazaa A., Nieminen M., Priori S. G., Swedberg K., ESC Committee for Practice Guidelines (CPG), ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal 2008 29 19 2388 2442 10.1093/eurheartj/ehn309
31. Wang A. Y., Sanderson J. E., Current perspectives on diagnosis of heart failure in long-term dialysis patients. The American Journal of Kidney Diseases 2011 57 2 308 319 2-s2.0-78751624559 10.1053/j.ajkd.2010.07.019
32. Hunt S. A., Abraham W. T., Chin M. H., Feldman A. M., Francis G. S., Ganiats T. G., Jessup M., Konstam M. A., Mancini D. M., Michl K., Oates J. A., Rahko P. S., Stevenson L. W., Jesup M., Casey D. E., Silver M. A., Yancy C. W., Smith S. C., Jacobs A. K., Buller C. E., Creager M. A., Ettinger S. M., Krumholz H. M., Kushner F. G., Lytle B. W., Nishimura R. A., Page R. L., Tarkington L. G., 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 119 14 e391 e479 2-s2.0-65549145093 10.1161/CIRCULATIONAHA.109.192065
33. Vasan R. S., Larson M. G., Benjamin E. J., Evans J. C., Reiss C. K., Levy D., Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. Journal of the American College of Cardiology 1999 33 7 1948 1955 2-s2.0-0032741126 10.1016/S0735-1097(99)00118-7
34. Wang T. J., Evans J. C., Benjamin E. J., Levy D., LeRoy E. C., Vasan R. S., Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003 108 8 977 982 2-s2.0-0041356972 10.1161/01.CIR.0000085166.44904.79 (Pubitemid 37048228)
35. Paulus W. J., Tschöpe C., Sanderson J. E., Rusconi C., Flachskampf F. A., Rademakers F. E., Marino P., Smiseth O. A., de Keulenaer G., Leite-Moreira A. F., Borbély A., Édes I., Handoko M. L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A. G., Brutsaert D. L., How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal 2007 28 20 2539 2550 2-s2.0-34548525319 10.1093/eurheartj/ehm037 (Pubitemid 47614269)
36. Pecoits-Filho R., Barberato S. H., Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron-Clinical Practice 2010 114 4 c242 c247 2-s2.0-74249093829 10.1159/000276575
37. National Kidney Foundation, K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. The American Journal of Kidney Diseases 2005 45 4, supplement 3 S1 S153
38. Zoccali C., Benedetto F. A., Mallamaci F., Tripepi G., Giacone G., Stancanelli B., Cataliotti A., Malatino L. S., Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney International 2004 65 4 1492 1498 2-s2.0-1642545133 10.1111/j.1523-1755.2004.00530.x (Pubitemid 38406992)
39. Foley R. N., Parfrey P. S., Kent G. M., Harnett J. D., Murray D. C., Barre P. E., Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. Journal of the American Society of Nephrology 2000 11 5 912 916 2-s2.0-0034056792 (Pubitemid 30241725)
40. Bello D., Shah D. J., Farah G. M., Di Luzio S., Parker M., Johnson M. R., Cotts W. G., Klocke F. J., Bonow R. O., Judd R. M., Gheorghiade M., Kim R. J., Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β -blocker therapy. Circulation 2003 108 16 1945 1953 2-s2.0-0142023855 10.1161/01.CIR.0000095029.57483.60 (Pubitemid 37296539)
41. Wizemann V., Schilling M., Dilemma of assessing volume state-the use and the limitations of a clinical score. Nephrology Dialysis Transplantation 1995 10 11 2114 2117 2-s2.0-0028790558
42. Charra B., Fluid balance, dry weight, and blood pressure in dialysis. Hemodialysis International 2007 11 1 21 31 2-s2.0-33846345848 10.1111/j.1542-4758.2007.00148.x (Pubitemid 46128675)
43. Katzarski K. S., Nisell J., Randmaa I., Danielsson A., Freyschuss U., Bergstrom J., A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. The American Journal of Kidney Diseases 1997 30 4 459 465 10.1016/S0272-6386(97)90302-4 (Pubitemid 27422290)
44. Chang S. T., Chen C. L., Chen C. C., Lin F. C., Wu D., Enhancement of quality of life with adjustment of dry weight by echocardiographic measurement of inferior vena cava diameter in patients undergoing chronic hemodialysis. Nephron-Clinical Practice 2004 97 3 c90 c97 2-s2.0-4043164305 10.1159/000078636 (Pubitemid 39077824)
45. Santoro A., Mancini E., Basile C., Amoroso L., Di Giulio S., Usberti M., Colasanti G., Verzetti G., Rocco A., Imbasciati E., Panzetta G., Bolzani R., Grandi F., Polacchini M., Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial. Kidney International 2002 62 3 1034 1045 2-s2.0-18744368078 10.1046/j.1523-1755.2002. 00511.x (Pubitemid 35316735)
46. Sinha A. D., Light R. P., Agarwal R., Relative plasma volume monitoring during hemodialysis aids the assessment of dry weight. Hypertension 2010 55 2 305 311 2-s2.0-74949132021 10.1161/HYPERTENSIONAHA.109.143974
47. Dasselaar J. J., Huisman R. M., de Jong P. E., Franssen C. F. M., Measurement of relative blood volume changes during haemodialysis: merits and limitations. Nephrology Dialysis Transplantation 2005 20 10 2043 2049 2-s2.0-27144549710 10.1093/ndt/gfi056 (Pubitemid 41510076)
48. Agarwal R., Kelley K., Light R. P., Diagnostic utility of blood volume monitoring in hemodialysis patients. The American Journal of Kidney Diseases 2008 51 2 242 254 2-s2.0-38149054004 10.1053/j.ajkd.2007.10.036
49. Wabel P., Chamney P., Moissl U., Jirka T., Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purification 2009 27 1 75 80 2-s2.0-58849150742 10.1159/000167013
50. Wizemann V., Wabel P., Chamney P., Zaluska W., Moissl U., Rode C., Malecka-Masalska T., Marcelli D., The mortality risk of overhydration in haemodialysis patients. Nephrology Dialysis Transplantation 2009 24 5 1574 1579 2-s2.0-65249173419 10.1093/ndt/gfn707
51. MacHek P., Jirka T., Moissl U., Chamney P., Wabel P., Guided optimization of fluid status in haemodialysis patients. Nephrology Dialysis Transplantation 2010 25 2 538 544 2-s2.0-75649111561 10.1093/ndt/gfp487
52. Mallamaci F., Benedetto F. A., Tripepi R., Rastelli S., Castellino P., Tripepi G., Picano E., Zoccali C., Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC: Cardiovascular Imaging 2010 3 6 586 594 2-s2.0-77956684371 10.1016/j.jcmg.2010.02.005
53. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., Ogawa H., Okumura K., Mukoyama M., Nakao K., Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994 90 1 195 203 2-s2.0-0028359997 (Pubitemid 24203680)
54. Hosoda K., Nakao K., Mukoyama M., Saito Y., Jougasaki M., Shirakami G., Suga S., Ogawa Y., Yasue H., Imura H., Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 1991 17 6, part 2 1152 1155 2-s2.0-0026079725
55. Yamamoto K., Burnett J. C. Jr., Jougasaki M., Nishimura R. A., Bailey K. R., Saito Y., Nakao K., Redfield M. M., Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996 28 6 988 994 10.1161/01.HYP.28.6.988 (Pubitemid 26415815)
56. Maisel A. S., Krishnaswamy P., Nowak R. M., McCord J., Hollander J. E., Duc P., Omland T., Storrow A. B., Abraham W. T., Wu A. H. B., Clopton P., Steg P. G., Westheim A., Knudsen C. W., Perez A., Kazanegra R., Herrmann H. C., McCullough P. A., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine 2002 347 3 161 167 2-s2.0-0037130155 10.1056/NEJMoa020233 (Pubitemid 34764819)
57. Hunt P. J., Richards A. M., Nicholls M. G., Yandle T. G., Doughty R. N., Espiner E. A., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clinical Endocrinology 1997 47 3 287 296 (Pubitemid 27395959)
58. Mant J., Doust J., Roalfe A., Barton P., Cowie M. R., Glasziou P., Mant D., McManus R. J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs F. D. R., Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment 2009 13 32 1 207 2-s2.0-70349459647 10.3310/hta13320
59. Kelder J. C., Cowie M. R., McDonagh T. A., Hardman S. M. C., Grobbee D. E., Cost B., Hoes A. W., Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 2011 97 12 959 963 2-s2.0-79956322718 10.1136/hrt.2010.220426
60. Balion C., Santaguida P. L., Hill S., Worster A., McQueen M., Oremus M., McKelvie R., Booker L., Fagbemi J., Reichert S., Raina P., Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evidence Report/Technology Assessment 2006 142 1 147 2-s2.0-58149359477
61. Januzzi J. L. Jr., The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Archives of Cardiovascular Diseases 2012 105 1 40 50 2-s2.0-84857790646 10.1016/j.acvd.2011.10.007
62. Codognotto M., Piccoli A., Zaninotto M., Mion M., Plebani M., Vertolli U., Tona F., Ruzza L., Barchita A., Boffa G. M., Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies. Clinical Chemistry 2007 53 12 2097 2104 2-s2.0-36649009536 10.1373/clinchem.2007.089656 (Pubitemid 350197292)
63. Takami Y., Horio T., Iwashima Y., Takiuchi S., Kamide K., Yoshihara F., Nakamura S., Nakahama H., Inenaga T., Kangawa K., Kawano Y., Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. The American Journal of Kidney Diseases 2004 44 3 420 428 2-s2.0-4444311314 10.1053/j.ajkd.2004.05.023 (Pubitemid 39164618)
64. Apple F. S., Murakami M. A. M., Pearce L. A., Herzog C. A., Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clinical Chemistry 2004 50 12 2279 2285 2-s2.0-9244250381 10.1373/clinchem.2004.035741 (Pubitemid 39552162)
65. Wang A. Y., Lam C. W., Yu C., Wang M., Chan I. H., Zhang Y., Lui S., Sanderson J. E., N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. Journal of the American Society of Nephrology 2007 18 1 321 330 2-s2.0-33845974912 10.1681/ASN. 2005121299 (Pubitemid 46053444)
66. Mallamaci F., Zoccali C., Tripepi G., Benedetto F. A., Parlongo S., Cataliotti A., Cutrupi S., Giacone G., Bellanuova I., Stancanelli B., Malatino L. S., Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney International 2001 59 4 1559 1566 2-s2.0-0035069834 10.1046/j.1523-1755.2001.0590041559.x (Pubitemid 32281248)
67. Tripepi G., Mattace-Raso F., Mallamaci F., Benedetto F. A., Witteman J., Malatino L., Zoccali C., Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension 2009 54 4 818 824 2-s2.0-70349661416 10.1161/HYPERTENSIONAHA.109.136804
68. Wang A. Y., Clinical utility of natriuretic peptides in dialysis patients. Seminars in Dialysis 2012 25 3 326 333
69. Wang A. Y., Sanderson J. E., Treatment of heart failure in long-term dialysis patients: a reappraisal. The American Journal of Kidney Diseases 2011 57 5 760 772 2-s2.0-79954601364 10.1053/j.ajkd.2011.01.014
70. Ritz E., Dikow R., Adamzcak M., Zeier M., Congestive heart failure due to systolic dysfunction: the cinderella of cardiovascular management in dialysis patients. Seminars in Dialysis 2002 15 3 135 140 2-s2.0-0036559911 10.1046/j.1525-139X.2002.00044.x (Pubitemid 41765923)
71. Özkahya M., Ok E., Cirit M., Aydin Ş., Akçiçek F., Başçi A., Dorhout Mees E. J., Regression of left ventricular hypertrophy in haemodialysis patient by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrology Dialysis Transplantation 1998 13 6 1489 1493 2-s2.0-0031779892 10.1093/ndt/13.6.1489 (Pubitemid 28254325)
72. Gunal A. I., Karaca I., Aygen B., Yavuzkir M., Dogukan A., Celiker H., Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. Journal of International Medical Research 2004 32 1 70 77 2-s2.0-0742289936 (Pubitemid 38159234)
73. Aslam F., Haque A., Haque J., Joseph J., Heart failure in subjects with chronic kidney disease: best management practices. World Journal of Cardiology 2010 2 5 112 117 10.4330/wjc.v2.i5.112
74. Abdo A. S., Basu A., Geraci S. A., Managing chronic heart failure patient in chronic kidney disease. The American Journal of Medicine 2011 124 1 26 28 2-s2.0-78650708081 10.1016/j.amjmed.2010.05.030
75. Mancini D. M., Katz S. D., Lang C. C., LaManca J., Hudaihed A., Androne A., Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003 107 2 294 299 2-s2.0-0037458127 10.1161/01.CIR.0000044914.42696.6A (Pubitemid 36135227)
76. Silverberg D. S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., Schwartz D., Yachnin T., Steinbruch S., Shapira I., Laniado S., Iaina A., The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology 2001 37 7 1775 1780 2-s2.0-0035370037 10.1016/S0735-1097(01)01248-7 (Pubitemid 32499958)
77. Silverberg D. S., Wexler D., Blum M., Keren G., Sheps D., Leibovitch E., Brosh D., Laniado S., Schwartz D., Yachnin T., Shapira I., Gavish D., Baruch R., Koifman B., Kaplan C., Steinbruch S., Iaina A., The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology 2000 35 7 1737 1744 2-s2.0-0034128813 10.1016/S0735-1097(00)00613-6 (Pubitemid 30342851)
78. van der Meer P., Groenveld H. F., Januzzi J. L. Jr., van Veldhuisen D. J., Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009 95 16 1309 1314 2-s2.0-67650766504 10.1136/hrt.2008.161091
79. Levin A., Thompson C. R., Ethier J., Carlisle E. J. F., Tobe S., Mendelssohn D., Burgess E., Jindal K., Barrett B., Singer J., Djurdjev O., Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. The American Journal of Kidney Diseases 1999 34 1 125 134 2-s2.0-0033053766 (Pubitemid 29318806)
80. Martinez-Vea A., Marcas L., Bardají A., Romeu M., Gutierrez C., García C., Compte T., Nogues R., Peralta C., Giralt M., Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease. Clinical Nephrology 2012 77 3 171 181 2-s2.0-84859506412
81. Schmid H., Schiffl H., Lederer S. R., Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. Current Opinion in Nephrology and Hypertension 2011 20 5 465 470 2-s2.0-80051798372 10.1097/MNH.0b013e3283497057
82. Foley R. N., Parfrey P. S., Morgan J., Barre P. E., Campbell P., Cartier P., Coyle D., Fine A., Handa P., Kingman I., Lau C. Y., Levin A., Mendelssohn D., Muirhead N., Murphy B., Plante R. K., Posen G., Wells G. A., Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International 2000 58 3 1325 1335 2-s2.0-0033857652 10.1046/j.1523-1755. 2000.00289.x
83. Besarab A., Bolton W. K., Browne J. K., Egrie J. C., Nissenson A. R., Okamoto D. M., Schwab S. J., Goodkin D. A., The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England Journal of Medicine 1998 339 9 584 590 2-s2.0-0032572913 10.1056/NEJM199808273390903 (Pubitemid 28385655)
84. Drüeke T. B., Locatelli F., Clyne N., Eckardt K., Macdougall I. C., Tsakiris D., Burger H., Scherhag A., Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England Journal of Medicine 2006 355 20 2071 2084 2-s2.0-33751002326 10.1056/NEJMoa062276 (Pubitemid 44749316)
85. Singh A. K., Szczech L., Tang K. L., Barnhart H., Sapp S., Wolfson M., Reddan D., Correction of anemia with epoetin alfa in chronic kidney disease. The New England Journal of Medicine 2006 355 20 2085 2098 2-s2.0-33750983605 10.1056/NEJMoa065485 (Pubitemid 44749317)
86. Pfeffer M. A., Burdmann E. A., Chen C., Cooper M. E., de Zeeuw D., Eckardt K., Feyzi J. M., Ivanovich P., Kewalramani R., Levey A. S., Lewis E. F., McGill J. B., McMurray J. J. V., Parfrey P., Parving H., Remuzzi G., Singh A. K., Solomon S. D., Toto R., A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine 2009 361 21 2019 2032 2-s2.0-70949108082 10.1056/NEJMoa0907845
87. Timmer S. A. J., de Boer K., Knaapen P., Götte M. J. W., van Rossum A. C., The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? Journal of Cardiac Failure 2009 15 4 353 361 2-s2.0-65249088498 10.1016/j.cardfail.2008.10. 024
88. Locatelli F., Aljama P., Canaud B., Covic A., de Francisco A., MacDougall I. C., Wiecek A., Vanholder R., Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study. Nephrology Dialysis Transplantation 2010 25 9 2846 2850 2-s2.0-77956255701 10.1093/ndt/gfq336
89. Kazory A., Ross E. A., Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 2008 117 7 975 983 2-s2.0-39449108561 10.1161/CIRCULATIONAHA.107. 742270 (Pubitemid 351272594)
90. Achinger S. G., Ayus J. C., Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? Journal of the American Society of Nephrology 2006 17 12, supplement 3 S255 S261 2-s2.0-33845241514 10.1681/ASN.2006080923 (Pubitemid 44865258)
91. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International Supplements 2009 76 S1 S2 10.1038/ki.2009.188
92. Navaneethan S. D., Palmer S. C., Vecchio M., Craig J. C., Elder G. J., Strippoli G. F., Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database of Systematic Reviews 2011 2 CD006023 2-s2.0-79953011018
93. Silver J., Rodriguez M., Slatopolsky E., FGF23 and PTH-double agents at the heart of CKD. Nephrology Dialysis Transplantation 2012 27 5 1715 1720 10.1093/ndt/gfs050
94. Faul C., Amaral A. P., Oskouei B., Hu M., Sloan A., Isakova T., Gutiérrez O. M., Aguillon-Prada R., Lincoln J., Hare J. M., Mundel P., Morales A., Scialla J., Fischer M., Soliman E. Z., Chen J., Go A. S., Rosas S. E., Nessel L., Townsend R. R., Feldman H. I., Sutton M. S. J., Ojo A., Gadegbeku C., Di Marco G. S., Reuter S., Kentrup D., Tiemann K., Brand M., Hill J. A., Moe O. W., Kuro-o M., Kusek J. W., Keane M. G., Wolf M., FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation 2011 121 11 4393 4408 2-s2.0-80555148939 10.1172/JCI46122
95. Fujii H., Kim J. I., Abe T., Umezu M., Fukagawa M., Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Internal Medicine 2007 46 18 1507 1512 2-s2.0-34948904385 10.2169/ internalmedicine.46.0269 (Pubitemid 47521045)
96. Weishaar R. E., Simpson R. U., Vitamin D3 and cardiovascular function in rats. Journal of Clinical Investigation 1987 79 6 1706 1712 2-s2.0-0023160699
97. Cozzolino M., Ronco C., The impact of paricalcitol on left ventricular hypertrophy. Contributions to Nephrology 2011 171 161 165 2-s2.0-79958168695 10.1159/000327170
98. Wu J., Garami M., Cheng T., Gardner D. G., 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. Journal of Clinical Investigation 1996 97 7 1577 1588 10.1172/JCI118582 (Pubitemid 26105467)
99. Bodyak N., Ayus J. C., Achinger S., Shivalingappa V., Ke Q., Chen Y., Rigor D. L., Stillman I., Tamez H., Kroeger P. E., Wu-Wong R. R., Karumanchi S. A., Thadhani R., Kang P. M., Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 16810 16815 2-s2.0-36749043736 10.1073/pnas.0611202104 (Pubitemid 350210947)
100. Wang A. Y., Lam C. W., Sanderson J. E., Wang M., Chan I. H., Lui S., Sea M. M., Woo J., Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. The American Journal of Clinical Nutrition 2008 87 6 1631 1638 2-s2.0-45749148626 (Pubitemid 351872624)
101. Park C. W., Oh Y. S., Shin Y. S., Kim C. M., Kim Y. S., Kim S. Y., Choi E. J., Chang Y. S., Bang B. K., Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. The American Journal of Kidney Diseases 1999 33 1 73 81 2-s2.0-0032893965
102. Ivarsen P., Povlsen J. V., Christensen K. L., Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study. Scandinavian Journal of Urology 2012 46 5 381 388 10.3109/00365599.2012.693131
103. Bucharles S., Barberato S. H., Stinghen A. E. M., Gruber B., Piekala L., Dambiski A. C., Custodio M. R., Pecoits-Filho R., Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Journal of Renal Nutrition 2012 22 2 284 291 2-s2.0-84856351047 10.1053/j.jrn.2011.07.001
104. Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., Bhan I., Agarwal R., Zoccali C., Wanner C., Lloyd-Jones D., Cannata J., Thompson B. T., Andress D., Zhang W., Packham D., Singh B., Zehnder D., Shah A., Pachika A., Manning W. J., Solomon S. D., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. The Journal of the American Medical Association 2012 307 7 674 684 10.1001/jama.2012.120
105. Ligtenberg G., Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Netherlands Journal of Medicine 1999 55 1 13 18 2-s2.0-0033032285 10.1016/S0300-2977(99) 00024-8 (Pubitemid 29313190)
106. Bernardi D., Bernini L., Cini G., Ghione S., Bonechi I., Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. The American Heart Journal 1985 109 3, part 1 539 545 2-s2.0-0022206580 (Pubitemid 16256706)
107. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F. A., Tripepi G., Bonanno G., Rapisarda F., Fatuzzo P., Seminara G., Cateliotti A., Stancanelli B., Malatino L. S., Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002 105 11 1354 1359 2-s2.0-0037133633 10.1161/hc1102.105261 (Pubitemid 34260428)
108. Badve S. V., Roberts M. A., Hawley C. M., Cass A., Garg A. X., Krum H., Tonkin A., Perkovic V., Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. Journal of the American College of Cardiology 2011 58 11 1152 1161 2-s2.0-80052365390 10.1016/j.jacc.2011.04.041
109. Ezekowitz J., McAlister F. A., Humphries K. H., Norris C. M., Tonelli M., Ghali W. A., Knudtson M. L., The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. Journal of the American College of Cardiology 2004 44 8 1587 1592 2-s2.0-5644266226 10.1016/j.jacc.2004.06.072 (Pubitemid 39369790)
110. Shlipak M. G., Browner W. S., Noguchi H., Massie B., Frances C. D., McClellan M., Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. The American Journal of Medicine 2001 110 6 425 433 2-s2.0-0035870561 10.1016/S0002-9343(01)00652-0 (Pubitemid 32452328)
111. Abbott K. C., Trespalacios F. C., Agodoa L. Y., Taylor A. J., Bakris G. L., β -blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Archives of Internal Medicine 2004 164 22 2465 2471 2-s2.0-10344266474 10.1001/archinte.164.22.2465 (Pubitemid 39628074)
112. Ghali J. K., Wikstrand J., van Veldhuisen D. J., Fagerberg B., Goldstein S., Hjalmarson A., Johansson P., Kjekshus J., Ohlsson L., Samuelsson O., Waagstein F., Wedel H., The influence of renal function on clinical outcome and response to β -blockade in systolic heart failure: insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF). Journal of Cardiac Failure 2009 15 4 310 318 2-s2.0-65349180809 10.1016/j.cardfail.2008.11. 003
113. Castagno D., Jhund P. S., McMurray J. J. V., Lewsey J. D., Erdmann E., Zannad F., Remme W. J., Lopez-Sendon J. L., Lechat P., Follath F., Höglund C., Mareev V., Sadowski Z., Seabra-Gomes R. J., Dargie H. J., Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure 2010 12 6 607 616 2-s2.0-77953001086 10.1093/eurjhf/hfq038
114. Cohen-Solal A., Kotecha D., van Veldhuisen D. J., Babalis D., Böhm M., Coats A. J., Roughton M., Poole-Wilson P., Tavazzi L., Flather M., Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure 2009 11 9 872 880 2-s2.0-69249154151 10.1093/eurjhf/hfp104
115. Cice G., Ferrara L., Di Benedetto A., Russo P. E., Marinelli G., Pavese F., Iacono A., Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology 2001 37 2 407 411 2-s2.0-0035131087 10.1016/S0735-1097(00) 01158-X
116. Cice G., Ferrara L., D'Andrea A., D'Isa S., Di Benedetto A., Cittadini A., Elvira Russo P., Golino P., Calabrò R., Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. Journal of the American College of Cardiology 2003 41 9 1438 1444 2-s2.0-0038408916 10.1016/S0735-1097(03)00241-9 (Pubitemid 36543357)
117. Ascenção R., Fortuna P., Reis I., Carneiro A. V., Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors. Revista Portuguesa de Cardiologia 2008 27 9 1169 1187 2-s2.0-57349181247
118. Acquarone N., Castello C., Antonucci G., Lione S., Bellotti P., Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. Journal of Cardiovascular Medicine 2009 10 1 13 21 2-s2.0-67651021500 10.2459/JCM.0b013e3283189533
119. Amann K., Tyralla K., Gross M., Schwarz U., Törnig J., Stefan Haas C., Ritz E., Mall G., Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney International 2003 63 5 1708 1713 2-s2.0-0037407195 10.1046/j.1523-1755.2003.00927.x (Pubitemid 36513316)
120. Amann K., Gassmann P., Buzello M., Orth S. R., Törnig J., Gross M. L., Magener A., Mall G., Ritz E., Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney International 2000 58 1 153 161 2-s2.0-0033918987 10.1046/j.1523-1755.2000.00163.x (Pubitemid 30429860)
121. McAlister F. A., Ezekowitz J., Tonelli M., Armstrong P. W., Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004 109 8 1004 1009 2-s2.0-1442334646 10.1161/01.CIR.0000116764.53225.A9 (Pubitemid 38282853)
122. Frances C. D., Noguchi H., Massie B. M., Browner W. S., McClellan M., Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Archives of Internal Medicine 2000 160 17 2645 2650 2-s2.0-0034715226
123. Ahmed A., Love T. E., Sui X., Rich M. W., Effects of angiotensin- converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. Journal of Cardiac Failure 2006 12 7 499 506 2-s2.0-33748356053 10.1016/j.cardfail.2006.05.008 (Pubitemid 44335822)
124. Tokmakova M. P., Skali H., Kenchaiah S., Braunwald E., Rouleau J. L., Packer M., Chertow G. M., Moyé L. A., Pfeffer M. A., Solomon S. D., Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation 2004 110 24 3667 3673 2-s2.0-20844451359 10.1161/01.CIR.0000149806.01354.BF (Pubitemid 39665255)
125. Bowling C. B., Sanders P. W., Allman R. M., Rogers W. J., Patel K., Aban I. B., Rich M. W., Pitt B., White M., Bakris G. C., Fonarow G. C., Ahmed A., Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial. International Journal of Cardiology 2013 167 1 151 156 2-s2.0-84855737908 10.1016/j.ijcard.2011.12.056
126. London G. M., Pannier B., Guerin A. P., Marchais S. J., Safar M. E., Cuche J. L., Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994 90 6 2786 2796 2-s2.0-0028657576
127. Cannella G., Paoletti E., Delfino R., Peloso G., Rolla D., Molinari S., Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. The American Journal of Kidney Diseases 1997 30 5 659 664 (Pubitemid 27465360)
128. Guerin A. P., Blacher J., Pannier B., Marchais S. J., Safar M. E., London G. M., Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001 103 7 987 992 2-s2.0-0035916234 (Pubitemid 32183805)
129. Zannad F., Kessler M., Lehert P., Grünfeld J. P., Thuilliez C., Leizorovicz A., Lechat P., Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney International 2006 70 7 1318 1324 2-s2.0-33748949733 10.1038/sj.ki.5001657 (Pubitemid 44435184)
130. Chang T. I., Shilane D., Brunelli S. M., Cheung A. K., Chertow G. M., Winkelmayer W. C., Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. The American Heart Journal 2011 162 2 324 330 2-s2.0-80051668331 10.1016/j.ahj.2011.05.004
131. Berger A. K., Duval S., Manske C., Vazquez G., Barber C., Miller L., Luepker R. V., Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. The American Heart Journal 2007 153 6 1064 1073 2-s2.0-34249683835 10.1016/j.ahj.2007.03.017 (Pubitemid 46823967)
132. Flather M. D., Yusuf S., Køber L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moyé L., Braunwald E., Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet 2000 355 9215 1575 1581 2-s2.0-0010838455 (Pubitemid 30240501)
133. Bakris G. L., Weir M. R., Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Archives of Internal Medicine 2000 160 5 685 693 2-s2.0-0034642827 (Pubitemid 30140419)
134. Khan N. A., Ma I., Thompson C. R., Humphries K., Salem D. N., Sarnak M. J., Levin A., Kidney function and mortality among patients with left ventricular systolic dysfunction. Journal of the American Society of Nephrology 2006 17 1 244 253 2-s2.0-33645453727 10.1681/ASN.2005030270
135. Gradman A. H., Papademetriou V., Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. The American Heart Journal 2009 157 6, supplement S17 S23 2-s2.0-65549108889 10.1016/j.ahj.2009.04.007
136. de Denus S., Tardif J., White M., Bourassa M. G., Racine N., Levesque S., Ducharme A., Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. A retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. The American Heart Journal 2006 152 4 705 712 2-s2.0-33748713630 10.1016/j.ahj.2006.05.030 (Pubitemid 44396894)
137. Palmer B. F., Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. The New England Journal of Medicine 2004 351 6 585 622 2-s2.0-3442888821 10.1056/NEJMra035279 (Pubitemid 39025174)
138. Granger C. B., McMurray J. J. V., Yusuf S., Held P., Michelson E. L., Olofsson B., Östergren J., Pfeffer M. A., Swedberg K., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. The Lancet 2003 362 9386 772 776 2-s2.0-0041909380 10.1016/S0140-6736(03)14284-5 (Pubitemid 37093917)
139. Cohn J. N., Tognoni G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England Journal of Medicine 2001 345 23 1667 1675 2-s2.0-0035818884 10.1056/NEJMoa010713 (Pubitemid 33126822)
140. Wong M., Staszewsky L., Latini R., Barlera S., Volpi A., Chiang Y., Benza R. L., Gottlieb S. O., Kleemann T. D., Rosconi F., Vandervoort P. M., Cohn J. N., Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. Journal of the American College of Cardiology 2002 40 5 970 975 2-s2.0-0037019554 10.1016/S0735-1097(02)02063-6 (Pubitemid 34994994)
141. Pfeffer M. A., McMurray J. J. V., Velazquez E. J., Rouleau J., Køber L., Maggioni A. P., Solomon S. D., Swedberg K., van de Werf F., White H., Leimberger J. D., Henis M., Edwards S., Zelenkofske S., Sellers M. A., Califf R. M., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The New England Journal of Medicine 2003 349 20 1893 1906 2-s2.0-0242490542 10.1056/NEJMoa032292 (Pubitemid 37409706)
142. Yusuf S., Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J. V., Michelson E. L., Olofsson B., Östergren J., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. The Lancet 2003 362 9386 777 781 2-s2.0-0041408234 10.1016/S0140-6736(03)14285-7 (Pubitemid 37093918)
143. Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H., Remuzzi G., Snapinn S. M., Zhang Z., Shahinfar S., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine 2001 345 12 861 869 2-s2.0-0035922441 10.1056/NEJMoa011161
144. Tobe S. W., Clase C. M., Gao P., McQueen M., Grosshennig A., Wang X., Teo K. K., Yusuf S., Mann J. F. E., Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011 123 10 1098 1107 2-s2.0-79953042820 10.1161/CIRCULATIONAHA.110.964171
145. Ahmed A., Fonarow G. C., Zhang Y., Sanders P. W., Allman R. M., Arnett D. K., Feller M. A., Love T. E., Aban I. B., Levesque R., Ekundayo O. J., Dell'Italia L. J., Bakris G. L., Rich M. W., Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. The American Journal of Medicine 2012 125 4 399 410 10.1016/j.amjmed.2011.10.013
146. Cice G., Di Benedetto A., D'Isa S., D'Andrea A., Marcelli D., Gatti E., Calabr R., Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. Journal of the American College of Cardiology 2010 56 21 1701 1708 2-s2.0-78349252300 10.1016/j.jacc.2010.03.105
147. Staessen J., Lijnen P., Fagard R., Verschueren L. J., Amery A., Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology 1981 91 3 457 465 2-s2.0-0019865836 (Pubitemid 12203819)
148. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B., Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ace inhibitors. Journal of Clinical Pharmacology 1993 33 1 40 45 2-s2.0-0027499036 (Pubitemid 23067505)
149. Weber K. T., Aldosterone in congestive heart failure. The New England Journal of Medicine 2001 345 23 1689 1697 2-s2.0-0035818917 10.1056/NEJMra000050 (Pubitemid 33126826)
150. Briet M., Schiffrin E. L., Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 2010 6 5 261 273 2-s2.0-77951879058 10.1038/nrneph.2010.30
151. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. The New England Journal of Medicine 1999 341 10 709 717 2-s2.0-0033517302 10.1056/NEJM199909023411001 (Pubitemid 29407370)
152. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine 2003 348 14 1309 1321 2-s2.0-0037417252 10.1056/NEJMoa030207 (Pubitemid 36384098)
153. Pitt B., White H., Nicolau J., Martinez F., Gheorghiade M., Aschermann M., van Veldhuisen D. J., Zannad F., Krum H., Mukherjee R., Vincent J., Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology 2005 46 3 425 431 2-s2.0-22844437062 10.1016/j.jacc.2005.04.038 (Pubitemid 41040281)
154. Edwards N. C., Steeds R. P., Stewart P. M., Ferro C. J., Townend J. N., Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial. Journal of the American College of Cardiology 2009 54 6 505 512 2-s2.0-67651048925 10.1016/j.jacc.2009.03.066
155. Taheri S., Mortazavi M., Shahidi S., Pourmoghadas A., Garakyaraghi M., Seirafian S., Eshaghian A., Ghassami M., Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation 2009 20 3 392 397 2-s2.0-67649770575
156. Taheri S., Mortazavi M., Pourmoghadas A., Seyrafian S., Alipour Z., Karimi S., A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi Journal of Kidney Diseases and Transplantation 2012 23 3 507 512
157. Chua D., Lo A., Lo C., Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clinical Cardiology 2010 33 10 604 608 2-s2.0-78349303033 10.1002/clc.20838
158. The Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure. The New England Journal of Medicine 1997 336 8 525 533
159. Shlipak M. G., Smith G. L., Rathore S. S., Massie B. M., Krumholz H. M., Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. Journal of the American Society of Nephrology 2004 15 8 2195 2203 2-s2.0-3543070534 10.1097/01.ASN.0000135121.81744.75 (Pubitemid 39031358)
160. Ahmed A., Rich M. W., Love T. E., Lloyd-Jones D. M., Aban I. B., Colucci W. S., Adams K. F., Gheorghiade M., Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. European Heart Journal 2006 27 2 178 186 2-s2.0-30344472115 10.1093/eurheartj/ehi687 (Pubitemid 43069034)
161. Thiemann D. R., Digitalis and hemodialysis is a bad combination. Journal of the American Society of Nephrology 2010 21 9 1418 1420 2-s2.0-77956551856 10.1681/ASN.2010070775
162. Chan K. E., Lazarus J. M., Hakim R. M., Digoxin associates with mortality in ESRD. Journal of the American Society of Nephrology 2010 21 9 1550 1559 2-s2.0-77956514750 10.1681/ASN.2009101047
163. Bleeker G. B., Bax J. J., Steendijk P., Schalij M. J., van der Wall E. E., Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment. Nature Clinical Practice Cardiovascular Medicine 2006 3 4 213 219 2-s2.0-33645381940 10.1038/ ncpcardio0505
164. Penicka M., Bartunek J., Lang O., Medilek K., Tousek P., Vanderheyden M., de Bruyne B., Maruskova M., Widimsky P., Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting. Journal of the American College of Cardiology 2007 50 14 1315 1323 2-s2.0-34648837688 10.1016/j.jacc.2007.03.070 (Pubitemid 47454688)
165. Shin S. H., Hung C. L., Uno H., Hassanein A. H., Verma A., Bourgoun M., Køber L., Ghali J. K., Velazquez E. J., Califf R. M., Pfeffer M. A., Solomon S. D., Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. Circulation 2010 121 9 1096 1103 2-s2.0-77949381073 10.1161/CIRCULATIONAHA.109.863795
166. McAlister F. A., Ezekowitz J., Hooton N., Vandermeer B., Spooner C., Dryden D. M., Page R. L., Hlatky M. A., Rowe B. H., Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. The Journal of the American Medical Association 2007 297 22 2502 2514 2-s2.0-34250311359 10.1001/jama.297.22.2502 (Pubitemid 46953404)
167. Cannizzaro L. A., Piccini J. P., Patel U. D., Hernandez A. F., Device therapy in heart failure patients with chronic kidney disease. Journal of the American College of Cardiology 2011 58 9 889 896 2-s2.0-84860390559 10.1016/j.jacc.2011.05.024
168. Boerrigter G., Costello-Boerrigter L. C., Abraham W. T., Sutton M. G., Heublein D. M., Kruger K. M., Hill M. R. S., McCullough P. A., Burnett J. C. Jr., Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. Journal of Cardiac Failure 2008 14 7 539 546 2-s2.0-49549111147 10.1016/j.cardfail.2008.03.009
169. Asif A., Salman L. H., Lopera G. G., Carrillo R. G., The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach. Kidney International 2011 79 12 1267 1269 2-s2.0-79957802254 10.1038/ki.2011.53
170. Ganda A., Weiner S. D., Chudasama N. L., Valeri A. M., Jadoon A., Shimbo D., Radhakrishnan J., Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clinical Nephrology 2012 77 5 366 375 10.5414/CN107169
171. Libetta C., Sepe V., Zucchi M., Pisacco P., Cosmai L., Meloni F., Campana C., Rampino T., Monti C., Tavazzi L., Dal Canton A., Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrology Dialysis Transplantation 2007 22 7 2013 2019 2-s2.0-34547816893 10.1093/ndt/gfm004 (Pubitemid 47244775)
172. McIntyre C. W., Haemodialysis-induced myocardial stunning in chronic kidney disease-a new aspect of cardiovascular disease. Blood Purification 2010 29 2 105 110 2-s2.0-77749318628 10.1159/000245634
173. Burton J. O., Jefferies H. J., Selby N. M., McIntyre C. W., Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clinical Journal of the American Society of Nephrology 2009 4 12 1925 1931 2-s2.0-73649083292 10.2215/CJN.04470709
174. Selby N. M., Lambie S. H., Camici P. G., Baker C. S., McIntyre C. W., Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis. The American Journal of Kidney Diseases 2006 47 5 830 841 2-s2.0-33646062538 10.1053/j.ajkd.2006.01.012
175. Selby N. M., Burton J. O., Chesterton L. J., McIntyre C. W., Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate. Clinical Journal of the American Society of Nephrology 2006 1 6 1216 1225 2-s2.0-33947666955 10.2215/CJN.02010606
176. MacRae J. M., Pandeya S., Humen D. P., Krivitski N., Lindsay R. M., Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. The American Journal of Kidney Diseases 2004 43 5 e17 e22 2-s2.0-18844471969
177. Charra B., Bergstrom J., Scribner B. H., Blood pressure control in dialysis patients: importance of the lag phenomenon. The American Journal of Kidney Diseases 1998 32 5 720 724 2-s2.0-0031796487 (Pubitemid 28516300)
178. Culleton B. F., Walsh M., Klarenbach S. W., Mortis G., Scott-Douglas N., Quinn R. R., Tonelli M., Donnelly S., Friedrich M. G., Kumar A., Mahallati H., Hemmelgarn B. R., Manns B. J., Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. The Journal of the American Medical Association 2007 298 11 1291 1299 2-s2.0-34548772315 10.1001/jama.298.11.1291 (Pubitemid 47443343)
179. Ayus J. C., Mizani M. R., Achinger S. G., Thadhani R., Go A. S., Lee S., Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. Journal of the American Society of Nephrology 2005 16 9 2778 2788 2-s2.0-33644812878 10.1681/ASN.2005040392
180. Chan C. T., Harvey P. J., Picton P., Pierratos A., Miller J. A., Floras J. S., Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003 42 5 925 931 2-s2.0-0242609869 10.1161/01.HYP.0000097605.35343.64 (Pubitemid 37413732)
181. Chan C., Floras J. S., Miller J. A., Pierratos A., Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrology Dialysis Transplantation 2002 17 8 1518 1521 2-s2.0-0035993293
182. Chan C. T., Greene T., Chertow G. M., Kliger A. S., Stokes J. B., Beck G. J., Daugirdas J. T., Kotanko P., Larive B., Levin N. W., Mehta R. L., Rocco M., Sanz J., Schiller B. M., Yang P. C., Rajagopalan S., Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials. Circulation: Cardiovascular Imaging 2012 5 2 251 261 10.1161/CIRCIMAGING.111.969923
183. Hamburger R. J., Christ P. G., Morris P. A., Luft F. C., Hypertension in dialysis patients: does CAPD provide an advantage? Advances in Peritoneal Dialysis 1989 5 91 96 2-s2.0-0024919798
184. Lameire N., Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International 1993 13 supplement 2 S394 S395 2-s2.0-0027296971 (Pubitemid 23261228)
185. Dasgupta I., Burden R., Blood pressure control before and after starting dialysis. Nephron-Clinical Practice 2005 99 3 c86 c91 2-s2.0-33645504265
186. Menon M. K., Naimark D. M., Bargman J. M., Vas S. I., Oreopoulos D. G., Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrology Dialysis Transplantation 2001 16 11 2207 2213 2-s2.0-0035173046 (Pubitemid 33062145)
187. Ateş K., Nergizolu G., Keven K., Şen A., Kutlay S., Ertürk S., Duman N., Karatan O., Ertu A. E., Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney International 2001 60 2 767 776 2-s2.0-0034926425 10.1046/j.1523-1755.2001.060002767.x (Pubitemid 32678921)
188. Enia G., Mallamaci F., Benedetto F. A., Panuccio V., Parlongo S., Cutrupi S., Giacone G., Cottini E., Tripepi G., Malatino L. S., Zoccali C., Long-term CAPD patients are volume expanded and display more severe left venticular hypertrophy than haemodialysis patients. Nephrology Dialysis Transplantation 2001 16 7 1459 1464 2-s2.0-0034943271 (Pubitemid 32640604)
189. Konings C. J., Kooman J. P., Schonck M., Struijk D. G., Gladziwa U., Hoorntje S. J., van der Wall Bake A. W., van der Sande F. M., Leunissen K. M. L., Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrology Dialysis Transplantation 2003 18 4 797 803 2-s2.0-0037385592 10.1093/ndt/gfg147 (Pubitemid 36432264)
190. Margetts P. J., Churchill D. N., Acquired ultrafiltration dysfunction in peritoneal dialysis patients. Journal of the American Society of Nephrology 2002 13 11 2787 2794 2-s2.0-0036838302 (Pubitemid 35216050)
191. Aşci G., Özkahya M., Duman S., Toz H., Erten S., Ok E., Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Peritoneal Dialysis International 2006 26 1 85 88 2-s2.0-33745485618 (Pubitemid 44339666)
192. Konings C. J., Kooman J. P., Schonck M., Gladziwa U., Wirtz J., van den Wall Bake A. W., Gerlag P. G., Hoorntje S. J., Wolters J., van der Sande F. M., Leunissen K. M. L., Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney International 2003 63 4 1556 1563 2-s2.0-0037379342 10.1046/j.1523-1755.2003.00887.x (Pubitemid 36350022)
193. Stack A. G., Molony D. A., Rahman N. S., Dosekun A., Murthy B., Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney International 2003 64 3 1071 1079 2-s2.0-0041429526 10.1046/j.1523-1755.2003.00165.x (Pubitemid 37013845)
194. Vonesh E. F., Snyder J. J., Foley R. N., Collins A. J., The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney International 2004 66 6 2389 2401 2-s2.0-20544432122
195. McMurray J. J. V., Pitt B., Latini R., Maggioni A. P., Solomon S. D., Keefe D. L., Ford J., Verma A., Lewsey J., Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation: Heart Failure 2008 1 1 17 24 2-s2.0-79958249630
196. Sever P. S., Gradman A. H., Azizi M., Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of the Renin-Angiotensin-Aldosterone System 2009 10 2 65 76 2-s2.0-67650495757 10.1177/1470320309104662
197. Pitt B., Filippatos G., Gheorghiade M., Kober L., Krum H., Ponikowski P., Nowack C., Kolkhof P., Kim S. Y., Zannad F., Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. European Journal of Heart Failure 2012 14 6 668 675 10.1093/eurjhf/hfs061
198. Chung E. S., Packer M., Lo K. H., Fasanmade A. A., Willerson J. T., Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- α in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003 107 25 3133 3140 2-s2.0-0038755661 10.1161/01.CIR.0000077913.60364.D2 (Pubitemid 36793081)
199. Mann D. L., McMurray J. J. V., Packer M., Swedberg K., Borer J. S., Colucci W. S., Djian J., Drexler H., Feldman A., Kober L., Krum H., Liu P., Nieminen M., Tavazzi L., van Veldhuisen D. J., Waldenstrom A., Warren M., Westheim A., Zannad F., Fleming T., Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004 109 13 1594 1602 2-s2.0-11144355760 10.1161/01.CIR.0000124490.27666.B2 (Pubitemid 38451714)
200. Kelland N. F., Webb D. J., Clinical trials of endothelin antagonists in heart failure: a question of dose? Experimental Biology and Medicine 2006 231 6 696 699 2-s2.0-33744942636 (Pubitemid 43845511)
201. Packer M., Califf R. M., Konstam M. A., Krum H., McMurray J. J., Rouleau J., Swedberg K., Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002 106 8 920 926 2-s2.0-0037143601 10.1161/01.CIR.0000029801.86489.50 (Pubitemid 34925324)
202. Reilly T., Schork M. R., Vasopressin antagonists: pharmacotherapy for the treatment of heart failure. Annals of Pharmacotherapy 2010 44 4 680 687 2-s2.0-77950611792 10.1345/aph.1M660
203. Sata Y., Krum H., The future of pharmacological therapy for heart failure. Circulation Journal 2010 74 5 809 817 2-s2.0-77951747397 10.1253/circj.CJ-10-0272